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ABSTRACT 
Background: The pharmacokinetic properties of pravastatin, particularly 
AUC and Cma ~, are variable by population. A description of the pharmacokinetic 
properties of pravastatin Mexican mestizos was not found in a search of MEDLINE/ 
PubMed (key terms: pravastatin, Mexican, and pharmacokinetics; years: 1966- 
2005). Because Mexicans and Japanese have common ancestors (Mongoloid 
group), they also have a common gene pool. This gene pool was modified by 
genetic "bottlenecks" that occurred when these populations migrated to the 
Americas and when the Mexican population mixed with the Spanish population 
during the 16th and 17th centuries. Previous tudies in Japanese subjects howed 
5 main mutations on the hepatic drug transporter OATP-C, resulting in higher Cma x
and AUC values compared with whites. In the Japanese population, the rates of 
expression of the *lb and "15 alleles were 46% and 15%, respectively. 
Objective: The aim of this study was to evaluate the pharmacokinetic prop- 
erties of pravastatin in healthy Mexican mestizo volunteers and to compare 
them with those in white and Japanese populations described in the literature. 
Methods: This open-label, uncontrolled pilot study of the pharmacokinet- 
ic properties of pravastatin was conducted at the Division of Pharmacology, 
Center for Research and Advanced Studies, Mexico City, Mexico. Healthy, adult, 
Mexican volunteers received a single dose of pravastatin 10 mg PO (tablet). 
High-performance liquid chromatography was used to determine plasma pra- 
vastatin concentrations between 15 minutes and 12 hours after dosing. 
Results: Twenty-four subjects (15 women, 9 men; mean age, 30.6 years) 
participated in the study. The mean (SD) Cma x was 9.5 (2.4) ng/mL; Tmax, 0.8 
(0.3) hours; AUC0_~, 35.7 (19.7) ng/mL • h; tl/2, 2.7 (1.1) hours; and mean residence 
time, 3.1 (1.1) hours. One volunteer (4%) had an AUC value that differed sub- 
stantially from the rest of the study population, producing a bimodal distribu- 
tion of the pharmacokinetic parameters. No adverse events were observed or 
reported during the trial. 
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Conclusions: In this small pilot study of the pharmacokinetic properties of 
pravastatin in Mexican mestizos, AUC was not statistically significantly differ- 
ent from previous studies, either in a white or Japanese population. However, 
we did not find the high values reported for Cma xin some Japanese subjects car- 
rying recently reported mutations on the pravastatin transporter. (Curr Ther 
Res Clin Exp. 2005;66:238-246) Copyright © 2005 Excerpta Medica, Inc. 
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INTRODUCTION 
Pravastatin is a cholesterol-lowering inhibitor of hydroxymethylglutaryl coen- 
zyme A reductase (statin), which is involved in the de novo synthesis of choles- 
terol. 1,2 The first available statin, mevastatin, was isolated from the fungus 
Penicillium citrinum but was not marketed ue to safety concerns (eg, hepato- 
toxicity). 3 Pravastatin is indicated for the treatment of hypercholesterolemia 
and the prevention of cardiovascular disease, diabetes mellitus, 4and renal dis- 
ease. 5,6 Once absorbed, pravastatin undergoes the first-pass effect as it enters 
the enterohepatic circulation, resulting in poor bioavailability (18%). 7 Prava- 
statin is metabolized in the stomach and duodenum. 2 
A previous study 8 in Japanese subjects showed 5 main mutations on the 
hepatic drug transporter OATP-C, resulting in higher Cma xand AUC values com- 
pared with those in whites. In the Japanese population, the rates of expression 
of the *lb and "15 alleles have been found to be 46% and 15%, respectively. 8 
Because Mexicans and Japanese have common ancestors (Mongoloid group), 
they also have a common gene pool. This gene pool was modified by genetic 
"bottlenecks" that occurred when these populations migrated to the Americas 
and when the Mexican population mixed with the Spanish population during 
the 16th and 17th centuries. 9 
Although the clinical efficacy of pravastatin in Mexican patients has been 
shown, l° a MEDLINE/PubMed search (key terms: pravastatin, Mexican, and phar- 
macokinetics; years: 1966-2005) revealed no published pharmacokinetic data 
for pravastatin in the Mexican population. Therefore, the aim of this study was 
to evaluate the pharmacokinetic properties of pravastatin in healthy Mexican 
mestizo volunteers and to compare them with those in white and Japanese pop- 
ulations described in the literature. 
SUBJECTS AND METHODS 
This open-label, uncontrolled pilot study of the pharmacokinetic properties of 
pravastatin was conducted at the Division of Pharmacology, Center for Research 
and Advanced Studies, Mexico City, Mexico. The local ethics committee revised 
and approved the study protocol. 
Healthy subjects (as determined by physical examination and laboratory 
tests [complete blood count, biochemistry, creatinine clearance]) aged 18 to 
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50 years who could read, understand, and sign an informed-consent form were 
eligible for the study. Subjects were excluded from the study if they had any 
known pathology, had ingested any drug in the previous 8 days, used any psy- 
chotropic drug, abused drugs or alcohol, or were unwilling to provide written 
informed consent. Women who were pregnant, possibly pregnant, or breastfeed- 
ing were also excluded from the study. 
Eligible subjects were recruited from a typical middle-class neighborhood 
in northern Mexico City. This middle-class group consists mainly of people of 
mestizo origin (the ancestry of this group is -60% Native American, -38% 
white, and -2% African 11,12) in Mexico City. 13 A correlation between middle eco- 
nomic income and mestizo origin in Mexico City has been found in a previous 
work. 13 
After an overnight fast, a 10-mg tablet of pravastatin was administered to each 
subject at 8:00 AM. A light lunch was served 3 hours later. High-performance liq- 
uid chromatography (HPLC) was used to determine plasma pravastatin concen- 
trations between 15 minutes and 12 hours after dosing. Blood samples were col- 
lected from the cubital vein by a qualified nurse at 0, 15, and 30 minutes and 1, 
2, 4, 8, 10, and 12 hours using Vacutainer heparin tubes (Becton, Dickinson and 
Co., Franklin Lakes, New Jersey). Seven milliliters of whole blood was kept after 
discarding 3 mL. Plasma was immediately separated by centrifugation (3500g at 
room temperature for 10 minutes) and kept frozen at -20°C until analysis (with- 
in 3 months). Pharmacokinetic properties were compared with data from pub- 
lished studies in white and Japanese populations. Spontaneous reports of ad- 
verse events were recorded. 
Vital signs (blood pressure, heart rate, and body temperature) were moni- 
tored before, during, and at the end of the trial. 
Equipment and Reactives 
An Agilent series 1100 with automatic degassing system, quaternary pump, 
heated column, and diode array was used for HPLC. The column was a Zorbax 
XDB-C18 4.6 x 150 mm (Waters, Milford, Massachusetts). The reagents were 
Milli-Q deionized water, acetonitrile (Tecsiquim, Mexico City, Mexico), monoba- 
sic sodium phosphate (NaHPO4), and dibasic potassium phosphate (K2HPO4) 
(J.T. Baker, Mexico City, Mexico). 
Extraction and Chromatography 
Pravastatin was extracted from 1 mL of plasma with C18 extra-clean columns 
(Alltech, Mexico City, Mexico). Conditioning was carried out with 2 mL of 
methanol and 1 mL of water. The internal standard was dicloxacillin. Extraction 
and chromatography were based on the published method of Otter and 
Mignat. 14 A washing step with 1 mL of water preceded the elution with 0.5 mL 
of acetonitrile:water 50:50. 
The mobile phase was phosphate buffer (20 mmol/L):acetonitrile 56:44 at 
1.0 mL/min. The temperature of the column was maintained at 40°C and run 
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time was 8 minutes. The detector was set to 239 nm, and the method was vali- 
dated according to Causon's procedures. 15
AUC was chosen as the response function. Correlation coefficients were always 
>0.999; precision was 14.5% at the lower limit of quantification (5 ng/mL) and 12.1% 
at the higher limit (200 ng/mL). The intraday and interday biases were always <13%. 
Pharmacokinetic and Statistical Analysis 
Basic pharmacokinetic model-independent parameters were calculated. 
Quartiles and frequency histograms were used to observe the distribution of Cma x
and AUC. Data are given as mean (SD). Best fits were chosen using Akaike crite- 
ria 16 provided by the P-Pharm program (Innaphase, Philadelphia, Pennsylvania), 
which measures the weighted sum of squares considering the number of param- 
eters and number of observations taking the natural ogarithm. Statistical com- 
parisons of AUC values were performed using raw data estimations based on SDs 
and CIs. We compared our data with those from previous studies 8,17-2° using 
1-way analysis of variance and the Tukey test. Statistical calculations were per- 
formed using Minitab version 14 (Minitab Inc., State College, Pennsylvania). 
RESULTS 
Twenty-four healthy volunteers (15 women, 9 men; mean age, 30.6 years) partici- 
pated in the study, and all of them completed it. In the women, mean (SD) age was 
33.6 (11.1) years and mean (SD) body weight was 56.0 (24.4) kg; in the men, the mean 
(SD) age was 29.1 (11.5) years and the mean (SD) body weight was 67.6 (27.8) kg. 
Baseline mean (SD) values for the vital signs were as follows: systolic/diastolic 
blood pressure, 101/65 (33/21) mm Hg; heart rate, 82 (17) bpm; and body tem- 
perature, 36.5°C (0.2°C). No significant changes in the mean values were observed 
after pravastatin administration. 
The mean plasma pravastatin concentrations are shown in Figure 1. Mean 
(SD) Cm~ ¢and Tm~ values were 9.5 (2.4) ng/mL and 0.8 (0.3) hours, respective- 
ly, giving an AUC0_ ~ of 35.7 (19.7) ng/mL • h (Table I). One volunteer had an out- 
lier AUC0_ ~ value, producing a bimodal distribution of the pharmacokinetic 
parameters. The tl/2 of subject 24 was not possible to fit, so the AUC is shown 
as AUC0_12. The mean Akaike value for individual fittings was 13.3. 
The mean tl/2 in the present study (2.7 [ 1.1] hours) was numerically greater than 
in previous tudies (Table II). 8,17-2° The mean variability of the parameters between 
patients in this study was 44% (Figure 2). The variability in AUC (55%) is explained 
in part by the subject with the outlying value. No adverse vents were reported. 
DISCUSSION 
Several studies of the pharmacokinetic parameters of pravastatin 10 mg have 
been published (Table [I). 8,17-20 Because the Mexican mestizos have a gene pool 
similar to that of Asian populations, J°-12 the results of this study were compared 
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Figure 1. Plasma pravastatin concentrations after a single lO-mg dose. The profile is 
similar to previous reports in white patients with hypercholesterolemia and 
numerically lower than levels observed in Japanese volunteers receiving the 
same dose. 
with Asian studies. One study 8in Japanese subjects found 5 common mutations 
on OATP-C that produce a 5-fold increase in Cm~ xand AUC. The expression rates 
of the *lb and ~15 alleles in the Japanese population have been found to be 46% 
and 15%, respectively. 8 In a white population, the expression rate of the ~15 allele 
was found to be 0%. 8 Our literature search revealed no data for the OATP-C 
genotype in Mexicans. A previous comparison 9 found the AUC of nifedipine to be 
more similar between Mexican and Japanese populations than between either of 
these 2 populations and whites. Ogawa et a118 evaluated the pharmacokinetic 
properties of pravastatin 10 mg in 84 healthy Japanese volunteers. They found 
that the Cma xvalues were 4.8% higher in these subjects compared with the rest 
of the study population. In the present study, AUC was increased in 4% of sub- 
jects, whereas Cma x was not increased in any of the subjects. In a study of 23 
healthy Japanese volunteers, Nishizato et al 8 reported 30ATP-C phenotypes (lb, 
lb/15, and 15/15). In these individuals, the Cma xvalues were 14, 27, and 49 ng/mL 
(Table II). All 3 values were numerically higher than the mean in the present 
study. Fukazawa et a119 reported a geometric mean Cma x of 13.3 ng/mL (range, 
8.2-21.3 ng/mL) and an AUC of 40.0 ng/mL • h (range, 28.1-57.0 ng/mL • h) in 
Japanese subjects. In the present study, the geometric mean of Cma xwas 9.1 ng/mL 
(range, 4.1-13.7 ng/mL), and the geometric mean of AUC was 31.4 ng/mL- h (range, 
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Table I. Pharmacokinetic properties of pravastatin 10 mg after PO administration. 
Patient Cmax' Tmax' AUCo-~, tl/2, M RT, 
No. ng/mL h Ka ng/mL • h h h 
1 1 3.7 1.0 1.74 28.8 2.4 2.5 
2 1 3.3 1.0 2.10 40.4 3.5 2.5 
3 10.3 0.3 2.60 26.6 3.5 1.4 
4 11.3 0.5 2.31 33.2 3.5 2.9 
5 10.2 1.0 1.94 35.7 3.5 2.8 
6 8.9 1.0 10.19 18.7 0.8 2.8 
7 7.1 0.5 2.04 20.3 3.5 2.1 
8 7.8 1.0 2.21 19.2 1.2 3.4 
9 7.9 1.0 2.04 32.1 3.5 2.9 
10 6.0 1.0 2.25 12.9 1.1 3.2 
11 6.9 0.5 2.08 20.2 3.5 1.6 
12 4.1 0.5 1.89 19.2 3.5 1.8 
1 3 9.5 0.5 2.48 18.7 3.5 1.2 
14 8.7 1.0 2.29 51.0 3.6 4.6 
15 7.8 0.3 1 3.18 32.6 2.7 3.5 
16 10.0 1.0 2.38 45.1 1.7 3.8 
1 7 10.3 1.0 1.28 33.3 1.0 3.1 
18 8.0 1.0 3.01 42.6 2.5 4.8 
19 9.2 1.0 2.01 32.6 3.5 2.9 
20 11.9 1.0 2.38 67.3 3.6 3.6 
21 9.7 0.5 2.57 34.2 1.2 4.0 
22 1 3.3 1.0 1.52 53.7 1.7 4.1 
23 12.3 0.5 2.57 105.8 4.0 5.3 
24 9.0 1.0 1.59 31.8 * 4.3 
Mean 9.5 0.8 2.95 35.7 2.7 3.1 
SD 2.4 0.3 2.76 19.7 1.1 1.1 
CV, % 25 36 94 55 40 34 
Ka = absorption rate constant; MRT = mean residence time; CV = coefficient of variation. 
*This value was an outlier and so has been omitted here. 
5.7-93.8 ng/mL • h). Based on these results, it is likely that no mestizo subjects 
included in the present study expressed the ~lb or "15 OATP-C alleles because 
these alleles produce phenotypes of Cma ~ of 14 and 49 ng/mL, respectively, and 
an AUC of 44.2 and 62.1 ng/mL • h, respectively (Table ll). 
On the other hand, Pan et a117 reported a mean Cma ~ of 11.6 ng/mL; tl/2, 
2.6 hours; and AUC, 31.3 ng/mL • h after administering pravastatin 10 mg to white 
patients with hypercholesterolemia. D ta from the present study in healthy 
Mexican mestizo volunteers are similar to those from the study by Pan et al. 17 
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Table II. Comparison of pharmacokinetic properties of pravastatin found in this study 
versus previous studies. 
Cma x, AUC0_o~ tlt~2' 
Study ng/mL ng/mL • h 
This study 9.5 35.7 2.7 
Ogawa et a118 14.0 36.0 2.5 
Pan et a117 11.6 31.3 2.6 
Nishizato et al 8 15/15 49.0 111.8 3.3 
Nishizato et al 8 1 b/15 27.0 62.1 2.7 
Nishizato et al 8 1 b/1 b 14.0 44.2 2.2 
Fukazawa et a119 1 3.3 40.0 - 
Sugimoto et al 2° 36.5 109.4 - 
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Figure 2. Histogram for the distribution of AUC0_ ~ of pravastatin. AUC0_~o shows 
polymorphic behavior, but did not reach the values observed in Japanese 
populations. 
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Because the methods for pharmacokinetic analysis in most published articles 
use mass spectrometry linked to HPLC, these studies are comparable. 1,2 Fur- 
thermore, the pharmacokinetic properties of pravastatin have been shown to 
be similar between men and women. 2° 
With pravastatin 10 mg, no accumulation has been reported when the drug is 
administered BID. The tl/2 of pravastatin 10 mg reported in most studies is between 
1.6 and 3.3 hours. 16-2° In the present study, tl/2 fell within that range in 20% of sub- 
jects. One subject showed a tl/2 between 4 and 6 hours. The mean tl/2 in the pres- 
ent study was slightly numerically higher compared with those of previous tudies, 
with the exception of the study by Mazzu et al, 21 in which the authors reported a
tl/2 of 5.5 hours with pravastatin 40 mg. Pravastatin has "flip-flop" pharmacokinet- 
ic properties (ie, absorption is slower than elimination), 7 so the observed tl/2 in all 
studies mainly represent drug absorption, and in some cases drug distribution, 
both of which can be influenced by the polymorphism on OATP-C. 
We recommend conducting enomic studies on the Mexican population to 
verify the presence of an OATP-C genotype. 
This study is considered a pilot study due to the small sample size and lim- 
ited statistics compared with previous studies, and because no genomic data 
were determined. However, it provides an indication of the pharmacokinetic 
properties in this mestizo population. 
CONCLUSIONS 
In this small pilot study of the pharmacokinetic properties of pravastatin i healthy 
Mexican mestizo volunteers, the AUC values were statistically similar to those 
previously reported in white and Japanese populations. On the other hand, Cma ~ 
and tl/2 were numerically similar to those in a white population but not to those in 
some Japanese populations, which was due to the presence of allele ~15 in OATP-C. 
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